Aricept is a prescription medication that contains the active ingredient donepezil. Donepezil belongs to the class of drugs known as acetylcholinesterase inhibitors and is used primarily in the management of cognitive symptoms associated with Alzheimer’s disease. Aricept is marketed as a pill available in strengths of 5 mg and 10 mg. In Hong Kong, the product is regulated by the Department of Health under the Pharmacy and Poisons Ordinance and is only dispensed with a physician’s prescription.
Donepezil enhances cholinergic neurotransmission by inhibiting the enzyme acetylcholinesterase. This enzyme normally breaks down acetylcholine, a neurotransmitter involved in memory and learning. By reducing acetylcholinesterase activity, donepezil increases the concentration of acetylcholine in synaptic clefts, which can modestly improve neuronal communication in brain regions affected by Alzheimer’s disease.
Aricept is approved in Hong Kong for the symptomatic treatment of mild to moderate Alzheimer’s disease. The medication does not cure the disease but may slow the progression of cognitive decline and improve functional abilities in some patients.
Standard dosing:
Initiate with 5 mg once daily, preferably in the evening.
After 4-6 weeks, the dose may be increased to 10 mg once daily based on clinical response and tolerability.
Administration: Swallow the tablet whole with a full glass of water. Do not crush, chew, or split the pill.
Missed dose: Take the missed dose as soon as remembered on the same day; do not double the next dose.
Overdose: Symptoms may include severe nausea, vomiting, excessive salivation, or slowed heart rate. Seek emergency medical care; supportive measures are the mainstay of treatment.
Discontinuation: Abrupt cessation is generally safe, but clinicians may consider a gradual taper in patients who have tolerated the medication long-term to monitor for rebound symptoms.
Regular clinical assessment is recommended to evaluate cognitive response, functional status, and tolerability.
This article provides educational information about Aricept and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Aricept may be used alongside other agents such as memantine, but clinicians should monitor for additive side effects and adjust dosing as needed.
Persistent nausea should be reported to a healthcare professional; dose reduction to 5 mg or taking the tablet with a small amount of food may help alleviate symptoms.
Routine baseline labs are not mandatory, but a review of liver function and cardiac status is advisable, especially in patients with pre-existing conditions.
Aricept (donepezil) is taken once daily as a tablet, whereas rivastigmine is often administered twice daily or via transdermal patch, and the side-effect profiles differ slightly.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be prepared to declare it at customs if required.
Bradycardia can occasionally lead to mild hypotension; patients should have their blood pressure checked regularly, especially if they have a history of cardiovascular disease.
No specific dietary restrictions are required, but excessive caffeine or alcohol may worsen dizziness; moderation is recommended.
Store tablets at room temperature, typically between 20 °C and 25 °C, away from moisture and direct sunlight.
Aricept is approved for mild to moderate disease; benefits in severe stages are less clear and should be evaluated on a case-by-case basis.
Generic formulations contain the same active ingredient and are bioequivalent; however, patients should ensure they receive medication approved by the Hong Kong Department of Health.
